Tripep AB (publ.) Interim Report, January - June 2005

• The loss after tax was SEK -11.0 million (-13.9 m). • Research and development costs were SEK 4.5 million (6.9 m), with an additional SEK 4.4 million capitalised in the first half-year 2005. • As yet, the company has no operating income, and thus, had no net sales in the period. • Earnings per share were SEK -0.73 (-1.11). • After the end of the period, the Board of Directors consummated a new issue with preferential rights for shareholders, pursuant to EGM approval. The issue was heavily over-subscribed, raising SEK 28 million for the company before issue costs. • Listing of the warrants F and G on the Stockholm Stock Exchange will take place on 29 August 2005. • All practical details ahead of alphaHGA’s phase I/II trial have been prepared. • All remaining treasury shares were divested. • A new series E stock option plan was inaugurated. For more information, please contact Jan Nilsson, Chief Executive Officer Tel: +46 (0)8 449 84 82, mobile: +46 (0)70 466 31 63 e-mail: jan.nilsson@tripep.se Anders Vahlne, Head of Research Tel: +46 (0)8 5858 1313, mobile: +46 (0)70 928 05 28 e-mail: anders.vahlne@labmed.ki.se

About Us

ChronTech has developed and further develops a patent pending new type of injection needle for a more effective uptake of genetic vaccines (IVIN) and vaccine and therapy for hepatitis D. ChronTech also have part ownership in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se.

Documents & Links